<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01219699</url>
  </required_header>
  <id_info>
    <org_study_id>CBYL719X2101</org_study_id>
    <secondary_id>2010-018782-32</secondary_id>
    <nct_id>NCT01219699</nct_id>
  </id_info>
  <brief_title>A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene</brief_title>
  <official_title>A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-man trial, in which BYL719 will be administered to adult patients with
      advanced solid tumors, whose tumors have an alteration of the PIK3CA gene and whose disease
      has progressed despite standard therapy or for whom no standard therapy exists. A combination
      of BYL719 with fulvestrant will also be investigated in post-menopausal patients with locally
      advanced or metastatic breast cancer whose tumors have an alteration of the PIK3CA gene. The
      single agent MTD dose expansion cohort and the fulvestrant combination MTD dose expansion
      cohort will also include ER+/HER2- breast cancer patients whose tumors have the wild type
      PIK3CA gene
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 5, 2010</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD (or RP2D) of oral BYL719 as single agent and in combination with fulvestrant</measure>
    <time_frame>February 2013</time_frame>
    <description>Incidence rate of dose limiting toxicities (DLT) (in the first cycle (of 28 days) of each investigated dose level).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall safety and tolerability of BYL719 as single agent and in combination with fulvestrant</measure>
    <time_frame>April 2014</time_frame>
    <description>Safety and tolerability: type, intensity, severity and seriousness of adverse events (AE) according to NCI CTCAE v. 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BYL719 as single agent and in combination with fulvestrant</measure>
    <time_frame>April 2014</time_frame>
    <description>plasma concentration-time profiles and derived basic PK parameters of BYL719, including but not limited to AUC0-tlast, AUC0-inf, Cmax, Tmax, CL/F, Vz/F and the terminal half-life (t1/2) and other PK parameters if deemed appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy of BYL719 as single agent and in combination with fulvestrant</measure>
    <time_frame>April 2014</time_frame>
    <description>Objective tumor response rate (ORR), defined as the sum of complete response and partial response as best reported response by RECIST 1.0 criteria (Novartis v2.0 guideline)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">221</enrollment>
  <condition>Advanced Solid Tumors With an Alteration of the PIK3CA Gene</condition>
  <condition>Estrogen Receptor Positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>BYL719</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene, and in patients whose tumors are have wild-type PIK3CA gene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BYL719 + fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In post-menopausal patients with estrogen receptor positive locally advanced or metastatic breast cancer whose tumors have an alteration of the PIK3CA gene, and in patients whose tumors are have wild-type PIK3CA gene</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BYL719</intervention_name>
    <description>BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.</description>
    <arm_group_label>BYL719</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene.
Fulvestrant is an estrogen receptor antagonist, administered by monthly intramuscular injection</description>
    <arm_group_label>BYL719 + fulvestrant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically-confirmed, advanced unresectable solid tumors who have
             progressed within three months before screening/baseline visit Only patients who have
             confirmed PIK3CA status (wild type, mutation or amplification) will be allowed for
             screening (patients participating in the combination arm must be eligible for
             treatment with fulvestrant)

          -  Availability of a representative formalin fixed paraffin embedded tumor tissue sample

          -  At least one measurable or non-measurable lesion

          -  Age ≥ 18 years

          -  World Health Organization (WHO) Performance Status ≤ 2

          -  Good organ (hepatic, kidney, BM) function at screening/baseline visit

        Exclusion Criteria:

          -  Brain metastasis unless treated and free of signs/symptoms attributable to brain
             metastasis in the absence of corticosteroid therapy (anti-epileptic therapy is
             allowed).

          -  Prior treatment with PI3K, AKT or mTOR inhibitor and failure to benefit

          -  Patient with peripheral neuropathy NCI-CTC Grade ≥ 3

          -  Patient with diarrhea NCI-CTC Grade ≥ 2

          -  Patient with acute or chronic pancreatitis

          -  Impaired cardiac function or clinically significant cardiac disease incl. unstable
             angina pectoris ≤ 3 months prior to starting study drug and Acute Myocardial
             Infarction (AMI) ≤ 3 months prior to starting study drug.

          -  Patients with clinically manifest diabetes mellitus, history of gestational diabetes
             mellitus or documented steroid-induced diabetes mellitus

          -  Women who are pregnant or breast feeding or adults of reproductive potential not
             employing an effective method of birth control

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco UCSF Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(4)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Univeristy SC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center/University of Texas MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced solid tumors</keyword>
  <keyword>mutation</keyword>
  <keyword>amplification</keyword>
  <keyword>wild type</keyword>
  <keyword>PIK3CA gene</keyword>
  <keyword>dose-escalation</keyword>
  <keyword>estrogen receptor positive breast cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

